%0 Journal Article
%A Quiroga, Borja
%A Soler, María José
%A Ortiz, Alberto
%A Jaravaca Mantecón, Carlos Jesús
%A Nava Pérez, Nathasha
%A Serra Martín, Marta
%A Sato, Yurika
%A Marin Franco, Antonio José
%A Pazmiño Zambrano, Diana Flor
%A Lucena Valverde, Rafael
%A Ortega Diaz, Mayra
%A Calderón González, Carmen
%A Cazorla López, Juan Manuel
%A Pereira, Mónica
%A González Parra, Emilio
%A Sánchez Horrillo, Ana
%A Sánchez González, Carmen
%A Toapanta, Néstor
%A Cigarrán Guldris, Secundino
%A Sánchez Hernández, Rosa
%A Pizarro Sánchez, Soledad
%A Muñiz Rincón, María
%A Garcia-Fernández, Nuria
%A Blanco Castro, Natalia
%A Collantes Mateo, Rocío
%A Quiroz Morales, Manuel Augusto
%A Escamilla-Cabrera, Beatriz
%A Berdud Godoy, Isabel
%A Gil-Casares Casanova, Beatriz
%A Leyva, Alba
%A Rojas, José
%A Gansevoort, Ron T
%A de Sequera, Patricia
%A SENCOVAC collaborative network
%T Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study.
%D 2022
%@ 2048-8505
%U http://hdl.handle.net/10668/19752
%X Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P  In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
%K COVID-19
%K SARS-CoV-2
%K booster
%K hemodialysis
%K vaccination
%~